KRAS and lung adenocarcinoma: In fact, KRAS mutations are the most common oncogenic mutation in lung adenocarcinoma and KRAS hyperactivation is highly associated with many complex immunological and inflammatory disorders, such as RA and diabetes, which are difficult to cure and drug resistance is common41.